Novo Nordisk to focus on patient outreach, prescribing doctors and subsidies to reach obesity goals

Today, around 125,000 severely obese patients in the US are being treated with one of Novo Nordisk’s obesity drugs. Still, the real demand is yet unclear to the Danish pharmaceutical firm.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

Obese patients can feel confused and stigmatized, and reaching out to men in particular can be difficult. On top of this, Danish pharmaceutical firm Novo Nordisk has recently been hit by big production issues.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading